Download the FREE ebook "Beating Myeloma: If I Knew Then What I Know Now" and arm yourself with the information about autologous stem cell transplantation, treatment options, and side effects that I wish I had known about when I began treatment.
“The risk (cardiomyopathy) ranged from about 60% higher in ovarian cancer to over 300% higher in multiple myeloma.”
If you’ve just been diagnosed with MM and you’re trying to figure out your therapy plan, you’ve got to wonder if the ends justifies the means when it comes to conventional multiple myeloma therapies…
Your increased risk of cardiovascular disease (CVD) in general and cardiomyopathy specifically is in addition to your risk of multiple myeloma (MM) relapse and your risk of a treatment-related secondary cancer. Among other side effect MM patients have to struggle with such as BIPN, endocrine disorders, etc.
I was first diagnosed in early 1994. I underwent SOC therapies until I reached multi-drug resistence (MDR) in 9/97 and was told “there’s nothing more we can do for you…”
CVD in the form of blood clots, atrial fibrillation, and cardiomyopathy all followed over the years.
By wondering if the end justifies the means I am asking if aggressive, expensive, painful therapies that cause short, long-term and late stage side effects are worth it?
To look at this problem differently, let me ask you are question. If you could reduce your risk of short, long-term and late stage side effects, while maintaining a positive prognosis, would you? Even if it means changing your diet, lifestyle, conventional therapy plan, etc?
Scroll down the page, post a question or a comment if you would like to learn more.
thanks and hang in there,
“…a new study published in The Lancet shows that (multiple myeloma survivors) have a higher risk of cardiovascular disease (CVD) than controls without cancer, due to a number of reasons.
These include the use of chemotherapeutic agents that have direct toxic effects on the heart, the effects of the cancer itself on the blood and vascular system, and risk factors common to both, such as obesity and dietary factors.
A few randomized trials have shown that certain specific CVDs are associated with certain cancer therapies, over the short- to medium-term.
Some observational studies indicated a greater risk of CVDs in people who survived cancer in adolescence and young adulthood compared to age-matched or general population controls. However, not much is known about the absolute increase in risk in cancer survivors as compared to individuals without cancer.
Moreover, the outcome studied in most cases is CVD as a combined outcome, which suggests that only survivors of some cancers have a higher CVD risk.
In contrast, other studies indicate that different cancers are associated with different types of CVD.
The subjects included survivors of the 20 leading cancers which account for over 90% of cancers, and five times as many controls, matched for age and sex. The cancer survivors were classified into 20 groups.
The CVD outcomes observed were:
The study looked at over 100,000 adult cancer patients who had survived at least one year after diagnosis, and more than 520,000 controls. Patients were followed up until one of the following occurred:
The main findings were that in 18 of these cancers, survivors had a 2-9 times higher risk of VTE, or blood clots formed in the veins. The greatest increase was with pancreatic cancer survivors who were at more than 9 times higher risk compared to controls, while prostate cancer patients were at 70% increased risk…
In 10 out of 20 cancers, including blood… the risk of heart failure and cardiomyopathy (permanently weakened heart muscle) was increased. The risk ranged from about 60% higher in ovarian cancer to over 300% higher in multiple myeloma.